the risk of viral transmission together with a shortage in blood supplies has focused attention on the development of human blood substitutes new jerseybased biotechnology company enzon has now been granted a patent for its red blood cell substitute which uses bovine cow haemoglobin the haemoglobin is modified by attaching hairlike strands of the polymer polyethylene glycol peg to the protein in order to reduce its recognition by the bodys immune system this peghaemoglobin circulates longer in the body producing fewer allergic reactions peghaemoglobin also eliminates the need for blood typing and matching enzon us 908 980 4500